MicroPort’s Wright Bid Creates New Ortho Player

Wright Medical’s decision to sell its hip and knee business wasn’t entirely unexpected. The buyer, the Chinese company MicroPort, may have surprised some, but changes in orthopedics and the device industry as a whole could make such deals more common.

Wright Medical Group NV’s decision to sell its hip and knee joint business shouldn’t really have surprised anyone. [See Deal] CEO Robert Palmisano – in the eyes of one Wall Street analyst – is a “money maker” who has generated significant returns for investors by guiding businesses like eye company IntraLase Corp. and peripheral vascular player ev3 Inc. into the arms of larger strategic acquirers, Abbott Laboratories Inc.’s Abbott Medical Optics Inc. (then called Advanced Medical Optics) and Covidien Ltd., respectively. [See Deal][See Deal] Wright watchers say Palmisano had set a similar course for Wright when he joined as CEO in 2011. Early on, he divided the company into two distinct businesses, one focusing on the high-growth extremities sector and the other centered on the low-growth large joint sector. Given the divergent fates of the two sectors, it wasn’t difficult to guess which business was on the way out.

The time was right for Wright. Palmisano, in a conference call, told analysts the company has made "significant progress" in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.